Drug Trial Radar · NCT06123754
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Nov 17, 2023
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects with resectable stage IIIA and IIIB (N2) NSCLC. Primary study endpoints are MPR rate assessed by BIPR and EFS assessed by BIRC.
Conditions
- Non-small Cell Lung Cancer
Interventions
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injectionDrug
The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injectionDrug
The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MPR by BIPRTime frame: Up to 5 years
- EFS by BIRCTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin cancer hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.